How much profit has Ucb made this year?
Ucb has made 837.65 M EUR this year.
Ucb Net Income 2024
Ucb Net Income
837.65 M EUR
Ticker
UCB.BR
ISIN
BE0003739530
WKN
852738
In 2024, Ucb's profit amounted to 837.65 M EUR, a 144.21% increase from the 343 M EUR profit recorded in the previous year.
The Ucb Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2029e | 1.89 |
| 2028e | 1.94 |
| 2027e | 1.75 |
| 2026e | 1.7 |
| 2025e | 1.32 |
| 2024e | 0.84 |
| 2023 | 0.34 |
| 2022 | 0.42 |
| 2021 | 1.06 |
| 2020 | 0.73 |
| 2019 | 0.79 |
| 2018 | 0.8 |
| 2017 | 0.75 |
| 2016 | 0.52 |
| 2015 | 0.62 |
| 2014 | 0.21 |
| 2013 | 0.21 |
| 2012 | 0.26 |
| 2011 | 0.24 |
| 2010 | 0.1 |
| 2009 | 0.51 |
| 2008 | 0.04 |
| 2007 | 0.16 |
| 2006 | 0.37 |
| 2005 | 0.75 |
| 2004 | 0.36 |
Ucb Revenue, EBIT, Net Income BE0003739530 · 852738
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Ucb, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ucb from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ucb’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Ucb. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Ucb’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Ucb’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ucb’s growth potential.
Ucb Revenue, EBIT and net profit per share
| Date | Ucb Revenue | Ucb EBIT | Ucb Net Income |
|---|---|---|---|
| 2029e | 8.41 B EUR | 0 EUR | 1.89 B EUR |
| 2028e | 8.14 B EUR | 1.95 B EUR | 1.94 B EUR |
| 2027e | 7.63 B EUR | 1.77 B EUR | 1.75 B EUR |
| 2026e | 7.54 B EUR | 1.78 B EUR | 1.7 B EUR |
| 2025e | 6.71 B EUR | 1.34 B EUR | 1.32 B EUR |
| 2024e | 5.8 B EUR | 737.24 M EUR | 837.65 M EUR |
| 2023 | 5.25 B EUR | 514 M EUR | 343 M EUR |
| 2022 | 5.52 B EUR | 679 M EUR | 418 M EUR |
| 2021 | 5.78 B EUR | 1.32 B EUR | 1.06 B EUR |
| 2020 | 5.35 B EUR | 1.1 B EUR | 732 M EUR |
| 2019 | 4.91 B EUR | 1.11 B EUR | 792 M EUR |
| 2018 | 4.63 B EUR | 1.11 B EUR | 800 M EUR |
| 2017 | 4.53 B EUR | 1.13 B EUR | 753 M EUR |
| 2016 | 4.15 B EUR | 796 M EUR | 520 M EUR |
| 2015 | 3.88 B EUR | 577 M EUR | 623 M EUR |
| 2014 | 3.34 B EUR | 379 M EUR | 209 M EUR |
| 2013 | 3.41 B EUR | 441 M EUR | 207 M EUR |
| 2012 | 3.46 B EUR | 415 M EUR | 256 M EUR |
| 2011 | 3.25 B EUR | 399 M EUR | 235 M EUR |
| 2010 | 3.22 B EUR | 415 M EUR | 103 M EUR |
| 2009 | 3.12 B EUR | 466 M EUR | 513 M EUR |
| 2008 | 3.6 B EUR | 531 M EUR | 42 M EUR |
| 2007 | 3.63 B EUR | 503 M EUR | 160 M EUR |
| 2006 | 2.52 B EUR | 597 M EUR | 367 M EUR |
| 2005 | 2.34 B EUR | 470 M EUR | 754 M EUR |
| 2004 | 3.33 B EUR | 484 M EUR | 361.1 M EUR |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 3.33 B EUR | 484 M EUR | 361.1 M EUR |
| 2005 | 2.34 B EUR | 470 M EUR | 754 M EUR |
| 2006 | 2.52 B EUR | 597 M EUR | 367 M EUR |
| 2007 | 3.63 B EUR | 503 M EUR | 160 M EUR |
| 2008 | 3.6 B EUR | 531 M EUR | 42 M EUR |
| 2009 | 3.12 B EUR | 466 M EUR | 513 M EUR |
| 2010 | 3.22 B EUR | 415 M EUR | 103 M EUR |
| 2011 | 3.25 B EUR | 399 M EUR | 235 M EUR |
| 2012 | 3.46 B EUR | 415 M EUR | 256 M EUR |
| 2013 | 3.41 B EUR | 441 M EUR | 207 M EUR |
| 2014 | 3.34 B EUR | 379 M EUR | 209 M EUR |
| 2015 | 3.88 B EUR | 577 M EUR | 623 M EUR |
| 2016 | 4.15 B EUR | 796 M EUR | 520 M EUR |
| 2017 | 4.53 B EUR | 1.13 B EUR | 753 M EUR |
| 2018 | 4.63 B EUR | 1.11 B EUR | 800 M EUR |
| 2019 | 4.91 B EUR | 1.11 B EUR | 792 M EUR |
| 2020 | 5.35 B EUR | 1.1 B EUR | 732 M EUR |
| 2021 | 5.78 B EUR | 1.32 B EUR | 1.06 B EUR |
| 2022 | 5.52 B EUR | 679 M EUR | 418 M EUR |
| 2023 | 5.25 B EUR | 514 M EUR | 343 M EUR |
| 2024e | 5.8 B EUR | 737.24 M EUR | 837.65 M EUR |
| 2025e | 6.71 B EUR | 1.34 B EUR | 1.32 B EUR |
| 2026e | 7.54 B EUR | 1.78 B EUR | 1.7 B EUR |
| 2027e | 7.63 B EUR | 1.77 B EUR | 1.75 B EUR |
| 2028e | 8.14 B EUR | 1.95 B EUR | 1.94 B EUR |
| 2029e | 8.41 B EUR | 0 EUR | 1.89 B EUR |
Ucb stock margins BE0003739530 · 852738
The Ucb margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ucb. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ucb.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Ucb's sales revenue. A higher gross margin percentage indicates that the Ucb retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Ucb's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Ucb's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ucb's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ucb. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ucb's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Ucb Margin History
| Ucb Gross margin | Ucb Profit margin | Ucb EBIT margin | Ucb Profit margin |
|---|---|---|---|
| 2029e | 67.5 % | 0 % | 22.52 % |
| 2028e | 67.5 % | 23.99 % | 23.87 % |
| 2027e | 67.5 % | 23.19 % | 22.99 % |
| 2026e | 67.5 % | 23.6 % | 22.52 % |
| 2025e | 67.5 % | 19.93 % | 19.72 % |
| 2024e | 67.5 % | 12.71 % | 14.44 % |
| 2023 | 67.5 % | 9.79 % | 6.53 % |
| 2022 | 69.66 % | 12.31 % | 7.58 % |
| 2021 | 75.11 % | 22.85 % | 18.31 % |
| 2020 | 74.51 % | 20.5 % | 13.69 % |
| 2019 | 74.19 % | 22.57 % | 16.12 % |
| 2018 | 74.14 % | 24.03 % | 17.27 % |
| 2017 | 73.51 % | 24.94 % | 16.62 % |
| 2016 | 71.02 % | 19.19 % | 12.54 % |
| 2015 | 70.15 % | 14.89 % | 16.07 % |
| 2014 | 68.51 % | 11.33 % | 6.25 % |
| 2013 | 67.34 % | 12.93 % | 6.07 % |
| 2012 | 68.69 % | 11.99 % | 7.39 % |
| 2011 | 68.79 % | 12.29 % | 7.24 % |
| 2010 | 67.28 % | 12.9 % | 3.2 % |
| 2009 | 67.11 % | 14.96 % | 16.46 % |
| 2008 | 68.18 % | 14.75 % | 1.17 % |
| 2007 | 71.13 % | 13.87 % | 4.41 % |
| 2006 | 78.56 % | 23.66 % | 14.55 % |
| 2005 | 76.51 % | 20.08 % | 32.21 % |
| 2004 | 78.33 % | 14.52 % | 10.83 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 78.33 % | 14.52 % | 10.83 % |
| 2005 | 76.51 % | 20.08 % | 32.21 % |
| 2006 | 78.56 % | 23.66 % | 14.55 % |
| 2007 | 71.13 % | 13.87 % | 4.41 % |
| 2008 | 68.18 % | 14.75 % | 1.17 % |
| 2009 | 67.11 % | 14.96 % | 16.46 % |
| 2010 | 67.28 % | 12.9 % | 3.2 % |
| 2011 | 68.79 % | 12.29 % | 7.24 % |
| 2012 | 68.69 % | 11.99 % | 7.39 % |
| 2013 | 67.34 % | 12.93 % | 6.07 % |
| 2014 | 68.51 % | 11.33 % | 6.25 % |
| 2015 | 70.15 % | 14.89 % | 16.07 % |
| 2016 | 71.02 % | 19.19 % | 12.54 % |
| 2017 | 73.51 % | 24.94 % | 16.62 % |
| 2018 | 74.14 % | 24.03 % | 17.27 % |
| 2019 | 74.19 % | 22.57 % | 16.12 % |
| 2020 | 74.51 % | 20.5 % | 13.69 % |
| 2021 | 75.11 % | 22.85 % | 18.31 % |
| 2022 | 69.66 % | 12.31 % | 7.58 % |
| 2023 | 67.5 % | 9.79 % | 6.53 % |
| 2024e | 67.5 % | 12.71 % | 14.44 % |
| 2025e | 67.5 % | 19.93 % | 19.72 % |
| 2026e | 67.5 % | 23.6 % | 22.52 % |
| 2027e | 67.5 % | 23.19 % | 22.99 % |
| 2028e | 67.5 % | 23.99 % | 23.87 % |
| 2029e | 67.5 % | 0 % | 22.52 % |
Ucb Aktienanalyse
What does Ucb do?
The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Ucb's Profit Margins
The profit margins of Ucb represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Ucb's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Ucb's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Ucb's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Ucb’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Ucb stock
How has the profit developed compared to last year?
The profit has increased by 144.21% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Ucb publish its earnings?
Ucb publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Ucb?
The profits of Ucb are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Ucb?
You can learn more about the earnings of Ucb by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Ucb pay?
Over the past 12 months, Ucb paid a dividend of 1.33 EUR . This corresponds to a dividend yield of about 0.81 %. For the coming 12 months, Ucb is expected to pay a dividend of 1.36 EUR.
What is the dividend yield of Ucb?
The current dividend yield of Ucb is 0.81 %.
When does Ucb pay dividends?
Ucb pays a quarterly dividend. This is distributed in the months of May, May, May, May.
How secure is the dividend of Ucb?
Ucb paid dividends every year for the past 26 years.
What is the dividend of Ucb?
For the upcoming 12 months, dividends amounting to 1.36 EUR are expected. This corresponds to a dividend yield of 0.83 %.
In which sector is Ucb located?
Ucb is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ucb kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ucb from 4/30/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.
When did Ucb pay the last dividend?
The last dividend was paid out on 4/30/2024.
What was the dividend of Ucb in the year 2023?
In the year 2023, Ucb distributed 1.3 EUR as dividends.
In which currency does Ucb pay out the dividend?
The dividends of Ucb are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Ucb
Our stock analysis for Ucb Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ucb Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
